Search clinical trials for: CHIR258,

Total 4 results

Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer | VEGF | Solid Tumors and Advanced Endometrial Cancer | Second-line Treatment

Italy, United Kingdom, Spain, Brazil, United States, Korea, Republic of, New Zealand
Novartis Pharmaceuticals

Completed

Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors

Cancer | Neoplasm | Tumors

United States
Novartis Pharmaceuticals
Chiron Corporation

Terminated

Safety of CHIR-258 (TKI258) in Advanced Solid Tumors

Neoplasms | Cancer | Tumors

United Kingdom
Novartis Pharmaceuticals

Completed

Bioavailability and Food Effect Study of TKI258 (CSF Capsules vs. FMI Capsules)in Adult Patients With Advanced Solid Tumors

Neoplasms | Cancer | Tumors

United States

3

Subscribe